Rankings / Cognitive — Prescription Stimulants

Bromantane (Ladasten)

Cognitive · Russian psychostimulant / actoprotector

Tier B

dopamineadaptogenactoprotectorbannedprescription
6.4 / 10
Tier B
Ev 4.5 Bn 5.0 Sf 9.0

What this is

Russian Soviet-era development (originally Soviet military for stress resistance); commercialized as Ladasten by Pharmstandard; Russian regulatory approval 1997 for asthenia (chronic fatigue with anxiety). Largest evidence base: the multicenter Russian asthenia trial (n=728). Distinguishing pharmacologic feature versus classical stimulants — induces dopaminergic effects via CREB-dependent transcription rather than direct release or reuptake inhibition; the practical correlates biohacker forums report are stimulation without acute jitteriness or rebound fatigue AND benefits that outlast the dosing window by ~1 month. Bromantane was implicated in positive doping tests at the Atlanta 1996 and Sydney 2000 Olympics involving Russian athletes — currently listed on the WADA Prohibited List (Class S6 stimulants). Competitive athletes should not use. Limited Western peer-reviewed pharmacology: Mikhaylova 2007 (ScienceDirect) on hippocampal synaptic plasticity remains the most-cited mechanism paper; Oliynyk 2012 PMC3762282 "Pharmacology of Actoprotectors" provides class context. No formal Western RCT. Sold gray-market in research-chemical channels with GMP variability and counterfeit risk; not FDA-approved. Practical caveats: novel actoprotector mechanism is interesting but the evidence base is Russian and largely industry-adjacent — read with the same skepticism applied to the broader Soviet/Russian nootropic tradition.

Mechanism

Adamantane-bromophenyl-amine; classified in Russian pharmacology as an "actoprotector" — a synthetic adaptogen that enhances physical and mental stress resistance without raising O2 consumption or heat production; proposed mechanism: CREB phosphorylation drives cAMP-response-element-mediated upregulation of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) — ~2-2.5x increase in rat hypothalamus 1.5-2 hr post-dose; striatal dopamine elevated for ~8 hr; mild serotonergic and GABAergic potentiation; "non-classical" stimulant — distinct mechanism from amphetamine (transcriptional rather than direct release/reuptake)

Dose & route

50-100 mg PO daily; onset of therapeutic effect 1-3 days

Citations

Links go to the source. If a link is dead or you want something re-checked, let me know.

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.